The flashcards below were created by user
sdespins
on FreezingBlue Flashcards.
-
A fully human IgG1 anti-TNF monoclonal antibody
Binds to soluble TNF-a and prevent its interaction with TNF receptor
Given subcutaneously; t1/2 = 10-20 days
Adalimumab
-
A recombinant, humanized antibody Fab fragment conjugated to a polyethylene glycol (PEG) with specificity to TNF-a
Neutralizes membrane-bound and soluble TNF-a
Given subcutaneously; t1/2 = 14 days
Certolizumab
-
A recombinant fusion protein consisting of 2 soluble TNF p75 receptor moieties linked to the Fc portion of the human IgG1
Binds to TNF-a and also inhibits lymphotoxin-a
Given subcutaneously; t1/2 = 4.5 days
Etanercept
-
A human monoclonal antibody with a high affinity for soluble and membrane-bound TNF-a
Given subcutaneously; t1/2 = 14 days
Golimumab
-
Infliximab
A chimeric (25% mouse; 75% human) IgG1 monoclonal antibody with high affinity for soluble and possibly membrane-bound TNF-a
Given via iv infusion; t1/2 = 9-12 days
-
Side Effects of TNF inhibitors
- Infections
- Possibly risk of lymphoma
- Injection/infusion reactions
-
-
-
-
-
-cept suffix
Fusion protein
-
A recombinant form of the endogenous IL-1 receptor antagonist (IL-1ra)
Given subcutaneously, t1/2 = 4-6 hours
Anakinra
-
A recombinant human anti-IL-1b monoclonal antibody that binds to IL-1b and prevents it from binding to IL-1 receptor
Given subcutaneously, t1/2 = 26 days
Canakinumab
-
A dimeric fusion protein consisting of the
ligand-binding domains of the human IL-1 receptor 1 domain (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP) fused to the Fc portion of human IgG1.
Given subcutaneously
Rilonacept
-
Adverse effects of IL-1 inhibitors
- Infections
- Injection site reactions
-
Humanized antibody that binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and inhibits
IL-6-mediated signaling through these receptors
t1/2: 11-23 days
Indications:
(1) given via iv or sc for rheumatoid arthritis; (2) given via iv for juvenile idiopathic arthritis (polyarticular or systemic)
Adverse effects: infections; injection/infusion reactions
Tocilizumab
-
Human monoclonal antibody that binds to p40 subunit shared by IL-12 and IL-23
Given sc for treating plaque psoriasis and psoriatic arthritis
Adverse effects: infections, injection site reactions
Ustekinumab
-
Fusion protein that complexes with costimulatory B7 molecules
T cell anergy and apoptosis
Abatacept
-
Chimeric partially humanized anti-CD20 antibody
B Cell Death inducing agent
Rituximab
-
Oral inhibitor of JAK pathway
Tofacitinib
|
|